Pioneering Precision Medicine for Cardiovascular Diseases
DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver dalcetrapib, the first pharmacogenetic precision medicine in cardiovascular disease that specifically targets patients with the AA genotype at rs1967309 location in the ADCY9 gene (ADCY9 AA genotype).
Dalcetrapib is currently being evaluated in the Dal-GenE-2 (DAL-302) Phase 3 cardiovascular clinical outcomes confirmatory trial aiming to reduce fatal and non-fatal myocardial infarction (MI) in 2000 patients with post-acute coronary syndrome (ACS) who have the ADCY9 AA genotype. This confirmatory trial follows the results of the dal-GenE trial which showed a 21% relative risk reduction (RRR) in fatal and non-fatal MI in 6,149 patients across 34 countries, and a 45% RRR in 1,200 patients in North America.
To date, dalcetrapib has been administered, with a good safety and tolerability profile, to over 15,000 patients with cardiovascular diseases and risk factors such as obesity, diabetes, and hypertension.
DalCor has completed the dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This trial was initiated to determine the ability of dalcetrapib to reduce cardiovascular (CV) morbidity and mortality in a population experiencing an acute coronary syndrome (ACS) within 1-3 months before randomization (N=6147) and identified as carrying the AA genotype at variant rs1967309 in the adenylate cyclase type 9 (ADCY9) gene, as determined by the cobas® ADCY9 genotype test.